|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMATOPOIESIS
From the Basic Research Laboratory, Division of Basic
Sciences, National Cancer Institute-Frederick; the Laboratory of
Allergic Diseases, National Institute of Allergy and Infectious
Diseases, National Institutes of Health, Bethesda, MD; and the
Department of Laboratory Medicine, School of Medicine, University of
California, San Francisco.
Stem cell factor (SCF) binds to c-Kit and is an important mediator
of survival, growth, and function of hematopoietic progenitor cells and
mast cells. Lyn and other Src family members are activated by SCF and
associate with phosphorylated tyrosine residues in the c-Kit
juxtamembrane region. However, studies using c-Kit mutants incapable of
directly recruiting Src family members suggest this kinase family plays
a minimal role in c-Kit stimulus-response coupling mechanisms. The
objective of this study was to specifically target Lyn and subsequently
address its role in SCF-mediated responses of primary hematopoietic
progenitor cells and mast cells. To this end, a dominant-inhibitory Lyn
mutant and Lyn-deficient mice were used. Transfection of normal murine
mast cells with kinase-inactive Lyn impaired SCF-induced growth.
Further, SCF-induced proliferation and chemotaxis of Lyn-deficient mast
cells were less than for wild-type mast cells. SCF-induced growth of
progenitor cells lacking Lyn was also reduced compared with that of
wild-type progenitor cells. Impairment of SCF-mediated responses of
Lyn-deficient mast cells and progenitor cells did not result from
reductions in surface expression of c-Kit. These studies demonstrate
that Lyn is required for normal SCF-mediated responses of primary
progenitors and for a differentiated lineage.
(Blood. 2001;98:343-350) Hematopoiesis is regulated by multiple mechanisms,
including interaction of cell surface receptors with growth factors and cytokines. These molecules aid in the survival, proliferation, and
differentiation of hematopoietic progenitors. One superfamily of
receptors that binds hematopoietic growth factors is the receptor tyrosine kinase (RTK) superfamily (reviewed in 1). The
cytokine receptor superfamily also plays an important role in this
process (reviewed in 2).
c-Kit is an RTK encoded by the c-kit proto-oncogene
(reviewed in3-5). The c-Kit ligand is stem cell factor
(SCF). The absence of either SCF or c-Kit is lethal, and decreases in
expression or function of ligand or receptor results in macrocytic
anemia, mast cell deficiency, aberrations in pigmentation, and
sterility (reviewed in 3,6,7). Inappropriate expression or
constitutive activation of c-Kit has also been associated with human
diseases, including mastocytosis, myeloid leukemia, small-cell lung
carcinoma, and gastrointestinal stromal cell tumors.8-12
The critical role of c-Kit in normal physiology and the
association of activated mutants with human disease highlights the importance of understanding its mechanism of action. Recent work has
demonstrated that SCF activates the Ras-Raf-Map kinase cascade, phosphatidylinositol 3 kinase (PI3K), and, in some lineages, the Jak/Stat pathway (reviewed in 13). SCF induces the
association of Src, Lyn, and Fyn with c-Kit and the activation of
multiple Src family members.14-20 Reduction in the
expression of Lyn using antisense oligonucleotides inhibits SCF-induced
proliferation.15 In addition, treatment of cells with PP1,
a Src family inhibitor, does not alter the in vitro kinase activity of
c-Kit but impairs SCF-induced cell-cycle progression and
growth.15,20,21 These data suggest that Lyn has an
important function in SCF-induced proliferation in hematopoietic cells.
However, several lines of evidence conflict with this hypothesis.
First, findings using leukemic cell lines treated with pharmacologic
inhibitors and antisense oligonucleotides may not be representative of
normal physiology. Second, studies with c-Kit mutants incapable of
directly associating with Src family members suggest this kinase family does not play a significant role in SCF-mediated
responses.17,19 However, indirect activation of Src family
members could be induced through other regions of c-Kit. Third, the
phenotype of Lyn-deficient mice is not consistent with the abrogation
of SCF-mediated responses, though compensatory mechanisms in vivo could
mask highly specific defects in SCF responsiveness.22-24
To understand the role of Lyn in c-Kit stimulus-response coupling
mechanisms in primary hematopoietic cells, we examined SCF-mediated responses of Lyn-deficient mast cells and lineage negative
(Lin Our studies indicate a reduction in both the frequency and the
proliferative potential of SCF-responsive progenitor cells from
Lyn-deficient mice. Further, proliferation and chemotaxis of
Lyn-deficient mast cells is reduced compared to normal mast cells.
Transfection of normal mast cells with a dominant-inhibitory Lyn mutant
dramatically inhibits SCF-induced growth. These findings demonstrate
that Lyn is required for normal proliferation and chemotaxis responses
mediated by c-Kit in progenitor cells and mast cells.
Animals
Mast cells
To purify Lin Site-specific mutagenesis of wild-type Lyn plasmid DNA Human Lyn complementary DNA (cDNA) in the pSVL vector (Pharmacia Biotech, Piscataway, NJ) was kindly provided by Dr Becky Vonakis and Dr Henry Metzger (NIAMS/NIH, Bethesda, MD). Site-directed mutagenesis was performed on the human Lyn cDNA using the Stratagene (La Jolla, CA) Quickchange kit according to the manufacturer's directions. Custom oligonucleotide primers (Life Technologies, Rockville, MD) were designed to convert lysine 275 to leucine. Lysine 275 is required for Lyn to bind adenosine triphosphate and subsequent kinase activity.28,29 Mutagenesis was confirmed by DNA sequencing using a Perkin-Elmer (Wellesley, MA) Dye Terminator Cycle Sequencing Reaction kit with AmpliTaq DNA polymerase. The sequence was analyzed using ABI Prism software, version 2.1.0. Immune complex kinase assays were performed on cells transfected with the K275L Lyn mutant and confirmed the loss of kinase activity (data not shown).Cell transfection BMMC were incubated for 4 to 6 hours in fresh growth medium, washed twice, and resuspended in IMDM supplemented with 10% FCS, 2 mM L-glutamine, and 1% penicillin-streptomycin. Aliquots of cells (107/250 µL) were placed in electroporation cuvettes (4-mm gap) and incubated for 10 minutes at room temperature, and plasmid was added at the indicated concentrations. After a 5-minute incubation at room temperature, cells were electroporated (Bio-Rad Gene Pulser, Hercules, CA) at 280 V and 960 µF. After additional incubation for 5 minutes at room temperature, cells were transferred to a tissue culture flask and resuspended in mast cell growth media. In some experiments, cells were cotransfected with plasmid encoding green fluorescence protein (GFP) to determine the frequency of transfection. This ranged from 15% to 40%, depending on the experiment. Expression of GFP was assessed using a Nikon (Tokyo, Japan) Diaphot microscope. Cells were harvested at the indicated times and lysed in buffer containing 1% Triton X-100, 10 mM Tris-HCl (pH 7.5), 50 mM NaCl, 5 mM EDTA, 30 mM sodium pyrophosphate, 25 mM -glycerol phosphate,
5 mM sodium orthovanadate, 0.1% P-nitrophenyl phosphate, and 1 mM phenylmethylsulfonyl fluoride.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting Proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to Immobilon (Millipore, Bedford, MA). Radiolabeled proteins were visualized using autoradiography, and Lyn protein was immunoblotted as described.15,20 Antibody specific for murine Lyn was purchased from Wako Pure Chemical Industries (clone 8; Osaka, Japan), and a monoclonal antibody that recognized human Lyn was purchased from Transduction Laboratories (Lexington, KY).Proliferation assays, cell-cycle analysis, and chemotaxis Proliferation was assessed using tritiated thymidine or by cell counts. For tritiated thymidine assays, wild-type and Lyn-deficient mast cells were washed twice and resuspended at 1 × 105 cells/mL in serum-free QBSF-58 media (Quality Biological, Gaithersburg, MD). Aliquots of cells (100 µL) were placed in 96-well plates, and 100 µL media alone or media supplemented with murine SCF, murine IL-3, or phorbol 12-myristate 13-acetate (PMA; Sigma, St Louis, MO) were added to triplicate wells at the indicated concentrations. In studies of transfected mast cells, the microtiter plates were incubated with growth factors for 24 hours at 37°C, 5% CO2. Untransfected mast cells were incubated for 60 hours under the same conditions. Each well of the microtiter plate was then pulsed with 1 µCi [3H]-thymidine (6.7 Ci/mM; NEN Life Science Products, Boston, MA) overnight and harvested (Tomtec Mach II semi-automatic cell harvester) onto glass fiber filter paper (Wallac, Turku, Finland). Filters were dried and counted in a liquid scintillation counter (model 1205; Pharmacia Biotech). Proliferation assays with progenitor cells were performed as described above, except that cells were resuspended at 5 × 104 cells/mL in QBSF-60 media (Quality Biological), and the plates were incubated for 4 days before harvest.Cell-cycle analysis was performed as follows. Murine BMMC were incubated for 18 hours in IMDM supplemented with 10% FCS but no growth factors, and they were harvested at the unstimulated time-point (T = 0). Murine SCF (100 ng/mL) was added, and cells were harvested at the times indicated in the text. For harvest, 2 × 106 cells were washed once in cold phosphate-buffered saline (PBS), resuspended in 1 mL 70% methanol in PBS, and stored at 4°C. After cells from all time-points were collected, they were pelleted and resuspended in 1 mL propidium iodide (Sigma) solution (50 µg/mL in 0.1% sodium-citrate and 0.1% Triton-X) and incubated with RNAse A (0.5 µg/mL) for 30 minutes at room temperature. Relative DNA content was analyzed by FACS (Becton Dickinson). For chemotaxis assays, wild-type and Lyn-deficient mast cells were washed twice with IMDM media without growth factors. Cells were then suspended in IMDM media supplemented with 0.5% bovine serum albumin (migration buffer). A total of 2.5 × 104 cells in 25 µL migration buffer was loaded on the top well of a chemotaxis chamber (96-well Chemotx, 5-µm pore size, 3.2-mm diameter; Neuroprobe, Gaithersburg, MD). The optimal concentration for SCF (100 ng/mL) or PMA (50 ng/mL) in 30 µL was added to the bottom wells of the chemotaxis chamber. Cells were allowed to migrate for 3 hours at 37°C in a 5% CO2 incubator. Cells that migrated were collected from the bottom wells, counted, and expressed as percentages of the total number of cells loaded at the top of the chemotaxis chamber. Chemokinesis was assessed by comparison of the migration of cells in the presence of SCF in both the upper and the lower wells. Colony assays in methylcellulose Lin wild-type and Lyn-deficient progenitor cells
selected for the expression of c-Kit were resuspended in serum-free
QBSF-60 (Quality Biological). Methylcellulose (Methocult M3100; Stem
Cell Technologies, Vancouver, BC, Canada) was diluted to a final
concentration of 1% in QBSF-60, 2 mM L-glutamine, and 100 U/mL
penicillin-streptomycin. Two milliliters methylcellulose solution,
containing 5000 cells in the presence or absence of 100 ng/mL murine
SCF, was dispensed into each of 3 small Petri dishes. Petri dishes were
incubated for 7 to 10 days at 37°C, 5% CO2. Colonies
were then counted and scored for size. Small colonies were defined as
10 to 25 cells, medium colonies as 25 to 100 cells, and large colonies
were 100 cells or more.
SCF-induced growth of Lyn-deficient progenitor cells is reduced SCF activates Lyn in the megakaryoblastic cell line Mo7e and in fetal liver cells.15,20 These findings led us to hypothesize that Lyn plays an important role in SCF-mediated responses of progenitor cells. To test this hypothesis, we examined the capacity of Lin hematopoietic progenitor cells from Lyn-deficient
animals to respond to SCF in vitro.
Lin
We next compared SCF-induced growth of wild-type and Lyn-deficient progenitor cells for a 5-day culture period in serum-free media. These data, shown in Figure 1B, demonstrated a reduction in the growth rate of Lyn-deficient progenitor cells in response to SCF. Reductions in SCF-induced proliferation could have resulted from a decrease in the numbers of cells that responded to SCF, a decrease in the proliferative potential of responding cells, or both. To assess these possibilities, colony formation in methylcellulose was assessed. Although no colonies were formed by either group in the absence of SCF, SCF induced smaller colonies of Lyn-deficient progenitors than the normal progenitors (Figure 1C). Further, the total number of colonies formed after culture in SCF was also decreased in the Lyn-deficient progenitors and in the normal progenitor cells (28 vs 131 colonies, respectively). This indicates that expression of Lyn increased the frequency of SCF-responsive progenitor cells and increased the proliferative potential. Similar results were obtained when SCF-induced colony formation was assessed in single-cell colony assays in liquid culture. Wild-type progenitors formed 150 colonies, of which 22 were large, after a 10-day incubation in SCF. In contrast, Lyn-deficient progenitors formed only 2 large colonies of 46 total colonies. Transfection with kinase-inactive Lyn inhibits SCF-induced growth of normal mast cells SCF is also critical in the development and function of mast cells. Therefore, we next examined the role of Lyn in SCF-mediated responses of this differentiated lineage by transiently transfecting normal murine BMMCs with a kinase-inactive (K275L) human Lyn mutant and examining SCF-induced proliferation. Figure 2A (lower panel) demonstrates that SCF-induced growth of murine mast cells transfected with kinase-inactive human Lyn was dramatically reduced compared to cells transfected with the vector control. Immunoblotting with antiserum specific for human Lyn demonstrated that the human Lyn protein was expressed in transfected cells (Figure 2A, upper panel). In some experiments, such as the one shown in Figure 2B, SCF-induced growth was slightly enhanced after transfection of mast cells with wild-type Lyn plasmid DNA. However, this mild effect was not observed in all experiments. Immunoblotting with antisera specific for human Lyn protein demonstrated that transfected cells expressed similar amounts of wild-type and mutant Lyn protein (Figure 2B, upper panel). These results indicate that the inhibition of SCF-induced growth by the kinase-inactive Lyn mutant does not result from toxicity associated with expressing high levels of Lyn protein.
Cotransfection studies with GFP indicated that the efficiency of transfection of mast cells ranged from 15% to 40%. This seems low, given the magnitude of the effect of the kinase-inactive Lyn mutant. However, because the GFP and Lyn constructs were in different vectors, the frequency of transfection of the Lyn construct might have been higher than the GFP construct. Further, it is possible that the amount of kinase-inactive Lyn required to alter cellular responses was lower than the threshold of detection for GFP using immunofluorescence. Reductions in SCF-mediated growth and chemotaxis of Lyn-deficient mast cells As a second approach to address the role of Lyn in SCF-mediated responses of mast cells, we used BMMCs from normal and Lyn-deficient mice. Previous studies have suggested that Lyn is not essential for IL-3-induced development of BMMCs in vitro.26 Indeed, we confirmed that 5-week culture of bone marrow mononuclear cells in IL-3 generated wild-type and Lyn-deficient BMMCs (data not shown). Figure 3 demonstrates that similar percentages of wild-type and Lyn-deficient cells expressed high-affinity IgE receptors (96.5% and 97.2%, respectively) and c-Kit (98.6% and 98.5%, respectively). Mean fluorescence intensity (MFI) of c-Kit staining of Lyn-deficient mast cells was approximately 20% higher than wild-type mast cells (15.4 and 12.6, respectively). In contrast, Lyn-deficient mast cells had a striking increase in the MFI of the high-affinity IgE receptor compared with wild-type mast cells (124.2 and 41.5, respectively). This demonstrates that similar percentages of wild-type and Lyn-deficient mast cells express c-Kit and suggests that Lyn-deficient mast cells have a slight increase in the numbers of c-Kit receptors on the cell surface. Interestingly, the expression of c-Kit on the surface of the Lyn-deficient mast cells increased with the age of the cultures. Overall, these studies indicated that BMMC could be generated from the bone marrow of wild-type and Lyn-deficient mice and that these mast cells were suitable for use in subsequent experiments comparing SCF-mediated responses.
SCF is a potent chemoattractant for mast cells (reviewed in
3,30). Therefore, we next examined the capacity of
Lyn-deficient mast cells to migrate in response to SCF. Figure
4A compares SCF-induced migration of
wild-type and Lyn-deficient mast cells. Although both populations of
cells exhibited the classic bell-shaped dose-response curve, the number
of Lyn-deficient mast cells that migrated in response to SCF was lower
than wild-type mast cells at each concentration of SCF examined. To
determine whether this defect in migration was specific for SCF, we
examined migration in response to PMA, a direct activator of protein
kinase C that works independently of Src family members. Figure 4B
demonstrates that PMA-induced migration was similar for Lyn-deficient
and wild-type mast cells. We next examined SCF-induced chemokinesis of
wild-type and Lyn-deficient mast cells. Figure 4C demonstrates that SCF
did not induce chemokinesis of either wild-type or Lyn-deficient mast
cells.
To determine whether Lyn is required for SCF-induced cell-cycle
progression, we performed cell-cycle analysis of wild-type and
Lyn-deficient mast cells after stimulation with SCF. Figure 5 demonstrates that 3% of Lyn-deficient
mast cells entered S phase after a 24-hour stimulation with SCF and
that 8% were in S phase after a 30-hour stimulation. In contrast, 20%
of wild-type controls were in S phase after culture for 24 and 30 hours
in SCF. These data indicate that the onset of S phase is delayed in
mast cells lacking Lyn and that fewer cells actually reach S phase
compared to wild-type controls. Similarly, the onset of the
G2/M phase was delayed in Lyn-deficient mast cells, and the
numbers of cells reaching mitosis was reduced.
Reductions in the numbers of cells capable of replicating DNA in
response to SCF should also be reflected in SCF-induced tritiated thymidine incorporation. Figure 6A
indicates that SCF-induced tritiated thymidine incorporation of the
Lyn-deficient mast cells was 45% lower than wild-type mast cells. In
contrast, tritiated thymidine incorporation of Lyn-deficient mast cells
in response to PMA was greater than wild-type mast cells (Figure 6B).
These data indicate that Lyn-deficient mast cells are capable of
responding normally to mitogens other than SCF.
Ectopic expression of wild-type Lyn enhances SCF-induced growth of Lyn-deficient mast cells To determine whether the reduction in SCF-induced growth of Lyn-deficient mast cells was directly related to the absence of Lyn, we examined whether expression of exogenous Lyn reconstituted SCF-induced proliferation. Lyn-deficient mast cells were transfected with wild-type human Lyn DNA, or vector control, and assessed for tritiated thymidine incorporation after culture for 24 hours in SCF. Immunoblotting with antiserum specific for human Lyn demonstrated that the human Lyn protein was expressed in transfected cells (data not shown). Figure 7A demonstrates that ectopic expression of Lyn protein led to increases in SCF-induced growth compared with the Lyn-deficient cells transfected with vector control. In fact, SCF-induced proliferation of Lyn-deficient mast cells transfected with wild-type Lyn was similar to the proliferation of wild-type mast cells transfected with vector controls.
To determine whether the reconstitution of SCF-induced growth of Lyn-deficient mast cells required Lyn kinase activity, cells were transfected either with vector control, kinase-inactive Lyn, or wild-type Lyn. Figure 7B demonstrates that expression of the kinase-inactive mutant, K275L Lyn, in Lyn-deficient mast cells reduced SCF-induced growth compared with the proliferation of cells transfected with vector control. Thus, increases in SCF-induced growth of Lyn-deficient mast cells by ectopic expression of Lyn is dependent on its kinase activity.
Previous studies have shown that SCF activates Src family members; however, little is known about the role of these kinases in the biologic responses of primary hematopoietic cells.15,17,19,20 Here we provide several lines of evidence demonstrating that Lyn contributes to SCF-mediated responses of mast cells and progenitor cells. First, the expression of a kinase-inactive Lyn protein reduced SCF-induced proliferation of wild-type mast cells (Figure 2). Second, SCF-induced growth of Lyn-deficient progenitor cells was reduced compared with wild-type progenitors (Figure 1). Third, SCF-induced migration and proliferation of Lyn-deficient mast cells was reduced compared with wild-type mast cells (Figures 4-7). Additionally, our data demonstrate that reductions in the growth of Lyn-deficient cells are specific for SCF and relate directly to a deficiency in the expression of Lyn protein. PMA-induced proliferation of Lyn-deficient mast cells and progenitors was greater than that of wild-type mast cells (Figure 6B and data not shown), and proliferation of Lyn-deficient mast cells could be reconstituted by ectopic expression of wild-type Lyn (Figure 7). The reduction in SCF-induced proliferation of Lyn-deficient mast cells
and Lin One major binding site for Src family members on murine c-Kit has been mapped to tyrosine 567.17 Correspondingly, tyrosine 568 of human c-Kit coprecipitates Src family members, and tyrosine 570 contributes to maximal interaction.16,19 Studies19 with Y568F human c-Kit suggested that Src family members contribute minimally to SCF-induced proliferation of transfected porcine aortic endothelial cells, and Besmer et al17 found the SCF-induced growth of mast cells transfected with a Y567F murine c-Kit mutant was only partially inhibited. Our findings with mast cells and progenitor cells demonstrate that Src family members make a more significant contribution to SCF-mediated responses than previously thought. This may be mediated, in part, by regions of human c-Kit other than tyrosines 568 and 570 and likely occurs indirectly. Similarly, studies of c-Kit mutants incapable of directly recruiting PI3 kinase suggested a minimal role for this lipid kinase in c-Kit stimulus-response coupling mechanisms.17,31,32 However, bone marrow-derived mast cells from p85PI3K-deficient mice do not respond to SCF, whereas FcERI-mediated responses are intact.33 Thus, differences in results using receptor mutants and approaches specifically targeting a particular signal transduction component have previously been noted. Studies have found that SCF-induced growth of mast cells treated with the Src family inhibitor PP1 is inhibited approximately 40%.17 This is a less dramatic inhibition than we observed in SCF-mediated responses of Lyn-deficient cells or wild-type mast cells transfected with kinase-inactive Lyn. However, the concentration of PP1 used (20 ng/mL) was low and might have been a suboptimal dose. Indeed, our previous work has demonstrated a 70% inhibition of SCF-induced proliferation of Mo7e cells at 10 µM PP1, a concentration shown to inhibit Lyn autophosphorylation activity in vitro, but not that of c-Kit.15,21 Lyn-deficient mice have normal T cells but exhibit severe B-cell abnormalities.22-24 Defects in IgE-mediated mast-cell function have also been reported.22 As they age, a striking splenomegaly develops in these animals, in part, from extramedullary hematopoiesis.34 Therefore, the phenotype of Lyn-deficient mice is not consistent with dramatic aberrations in c-Kit signaling. It is likely that SCF synergy with other growth factors compensates for the defects in SCF-mediated responses of Lyn-deficient mast cells and progenitor cells in vivo. In this regard, the difference in SCF-mediated responses of Lyn-deficient and wild-type cells in vitro, was most dramatic when studies were performed in serum-free media. Less notable differences in SCF-mediated responses of wild-type and Lyn-deficient cells were observed in studies performed in media supplemented with fetal calf serum (data not shown). Synergistic interaction of growth factors in vivo may explain why Lyn-deficient mice generate mast cells and are not anemic. Our data demonstrate that Lyn contributes to SCF-mediated proliferation of mast cells and hematopoietic progenitor cells; however, Lyn is not essential for these responses. Lyn-deficient cells still migrate and proliferate in response to SCF, albeit to a limited extent (Figures 1, 2, 4-7). In addition, the transfection of normal mast cells with kinase-inactive Lyn does not completely eliminate SCF-induced growth (Figure 2). One potential explanation of these findings is that other Src family members compensate for the loss of Lyn. Indeed, SCF activates multiple Src-related kinases, including Fyn.17,19 In this regard, SCF-induced growth of Lyn-deficient mast cells transfected with kinase-inactive Lyn was reduced compared with that of cells transfected with vector control (Figure 7B). These data support a role for multiple Src family members in SCF-mediated responses. SCF also activates the Ras-Raf-MAP kinase cascade, the Jak/Stat pathway, and PI3 kinase. Studies with pharmacologic inhibitors, c-Kit receptor mutants, and p85PI3K-deficient mice have shown that the PI3 kinase pathway contributes to SCF-mediated survival and growth of mast cells.17,31-33 Thus, the activation of Src-independent signal transduction pathways also likely accounts for the capacity of Lyn-deficient hematopoietic cells to respond to SCF. Lyn has been reported to act as both a positive and a negative regulator of various cell stimuli. Corey et al29 demonstrated that Lyn is critical for G-CSF-mediated growth of a lymphoblastoid cell line. In contrast, Lyn plays a role in the negative regulation of BCR, IgE, and IL-4 receptor signaling.22-24,35-37 Therefore, the cellular context is critical in determining whether Lyn contributes to the positive or the negative regulation of signaling pathways. The present study demonstrates that Lyn is important in the SCF-induced proliferation and chemotaxis of primary mast cells and in the proliferation of normal hematopoietic progenitor cells. Constitutive activation of Lyn has been reported in leukemic cell lines and primary leukemic blast cells.38 Elucidation of Lyn-dependent signaling pathways leading to proliferation may aid in the development of therapies for myeloid leukemias.
We thank Dr Douglas Lowy for review of this manuscript and for many helpful discussions. We also thank Dr Becky Vonakis and Dr Henry Metzger for providing human Lyn cDNA, and we thank Louise Finch in the Flow Cytometry Laboratory for her efforts and expertise.
Submitted December 7, 2000; accepted March 26, 2001.
Supported in part by National Institutes of Health grant HL54476.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Diana Linnekin, Basic Research Laboratory, Division of Basic Sciences, National Cancer Institute-Frederick, Bldg 567, Rm 226, Frederick, MD 21702; e-mail: dlinnekin{at}mail.ncifcrf.gov.
1. Paulson RF, Bernstein A. Receptor tyrosine kinases and the regulation of hematopoiesis. Semin Immunol. 1995;7:267-277[CrossRef][Medline] [Order article via Infotrieve]. 2. Cosman D. The hematopoietin receptor superfamily. Cytokine. 1993;5:95-106[CrossRef][Medline] [Order article via Infotrieve]. 3. Galli SJ, Zsebo KM, Geissler EN. The kit ligand, stem cell factor. Adv Immunol. 1994;55:1-96[Medline] [Order article via Infotrieve].
4.
Broudy VC.
Stem cell factor and hematopoiesis.
Blood.
1997;90:1345-1364 5. Ashman LK. The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol. 1999;31:1037-1051[CrossRef][Medline] [Order article via Infotrieve]. 6. Fleishman RA. From white spots to stem cells: the role of the kit receptor in mammalian development. Trends Genet. 1993;9:285-290[CrossRef][Medline] [Order article via Infotrieve]. 7. Morrison-Graham K, Takahashi Y. Steel factor and c-Kit receptor: from mutants to a growth factor system. Bioessays. 1993;15:77-83[CrossRef][Medline] [Order article via Infotrieve].
8.
Inoue M, Kyo S, Fujita M, Enomoto T, Kondoh G.
Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors.
Cancer Res.
1994;54:3049-3053
9.
Nagata H, Worobec AS, Oh CK, et al.
Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.
Proc Natl Acad Sci U S A.
1995;92:10560-10564
10.
Krystal GW, Hines SJ, Organ CP.
Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor.
Cancer Res.
1996;56:370-376
11.
Hirota S, Isozaki K, Moriyama Y, et al.
Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.
Science.
1998;279:577-580
12.
Beghini A, Peterlongo P, Ripamonti CB, et al.
C-kit mutations in core binding factor leukemias.
Blood.
2000;95:726-727 13. Linnekin D. Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol. 1999;31:1053-1074[CrossRef][Medline] [Order article via Infotrieve].
14.
Blume-Jensen P, Ronnstrand L, Gout I, Waterfield MD, Heldin CH.
Modulation of Kit/stem cell factor receptor-induced signaling by protein kinase C.
J Biol Chem.
1994;269:21793-21802
15.
Linnekin D, DeBerry CS, Mou S.
Lyn associates with the juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells.
J Biol Chem.
1997;272:27450-27455
16.
Price DJ, Rivnay B, Fu Y, Jiang S, Avraham S, Avraham H.
Direct association of Csk homologous kinase (CHK) with the diphosphorylated site Tyr568/570 of the activated c-KIT in megakaryocytes.
J Biol Chem.
1997;272:5915-5920 17. Timokhina I, Kissel H, Stella G, Besmer P. Kit signaling through PI3-kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation. EMBO J. 1998;17:6250-6262[CrossRef][Medline] [Order article via Infotrieve]. 18. Price DJ, Rivnay B, Avraham H. CHK down-regulates SCF/KL-activated Lyn kinase activity in Mo7e megakaryocytic cells. Biochem Biophys Res Commun. 1999;259:611-616[CrossRef][Medline] [Order article via Infotrieve]. 19. Lennartsson J, Blume-Jensen P, Hermanson M, Ponten E, Carlberg M, Ronnstrand L. Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction. Oncogene. 1999;18:5546-5553[CrossRef][Medline] [Order article via Infotrieve]. 20. Mou S, Linnekin D. Lyn is activated during late G1 of stem-cell-factor induced cell cycle progression in haemopoietic cells. Biochem J. 1999;342:163-170.
21.
Broudy VC, Lin NL, Liles WC, et al.
Signaling via Src family kinases is required for normal internalization of the receptor c-Kit.
Blood.
1999;94:1979-1986 22. Hibbs ML, Tarlinton DM, Armes J, et al. Multiple defects in the immune system of Lyn-deficient mice, culminated in autoimmune disease. Cell. 1995;83:301-311[CrossRef][Medline] [Order article via Infotrieve]. 23. Nishizumi H, Taniuchi I, Yamanashi Y, et al. Impaired proliferation of peripheral B cells and indication of autoimmune disease in Lyn-deficient mice. Immunity. 1995;3:549-560[CrossRef][Medline] [Order article via Infotrieve]. 24. Chan VW, Meng F, Soriano P, DeFranco AL, Lowell CA. Characterization of the B lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and down-regulation. Immunity. 1997;7:69-81[CrossRef][Medline] [Order article via Infotrieve].
25.
Lorenz U, Bergemann AD, Steinberg HN, et al.
Genetic analysis reveals cell type-specific regulation of receptor tyrosine kinase c-Kit by the protein tyrosine phosphatase SHP1.
J Exp Med.
1996;184:1111-1126 26. Nishizumi H, Yamamoto T. Impaired tyrosine phosphorylation and Ca2+ mobilization, but not degranulation, in Lyn-deficient bone marrow-derived mast cells. J Immunol. 1997;158:2350-2355[Abstract]. |
Top
Abstract
Introduction
/
) proliferated more slowly than
wild-type cells (
) in response to SCF. Mononuclear cells from bone
marrow from wild-type and Lyn-deficient mice were isolated using
lymphocyte separation media. Lin
) is reduced compared with
normal cells (
). Wild-type and Lyn-deficient
LinnegKitpos progenitor cells were resuspended
in 1% methylcellulose with QBSF-60 media in the presence or absence of
murine SCF (100 ng/mL). Five thousand cells were plated per
35-mm2 Petri dish. After an 8-day incubation, the size and
number of colonies were determined for each group. Data represent the
mean and standard deviation of triplicate samples. No colonies formed
in the absence of SCF. Small colonies were defined as those containing
10 to 25 cells, medium colonies as those containing 25 to 100 cells,
and large colonies as those containing 100 cells or more.
) or vector (V) control (
) and Lyn-deficient (- - -) mast
cells were incubated in 100 ng/mL murine SCF. At the times indicated,
cells were assessed for cell-cycle progression as described in
"Materials and methods." The experiment was performed 3 times, and
the data shown are representative of the results of each.
